Biotech Values

[DewDiligence]

Nice call—Xarelto looks like a good bet for approval in ACS at the lower dose (according to the FDA briefing docs at #msg-75808358). Still, I find it curious that JNJ submitted a standalone sNDA for Xarelto in the PCI component of ACS (#msg-75391993), and I wonder if the FDA ought to review the two Xarelto ACS submissions together and whether the advisory panel will opine on this question.